



Food and Drug Administration
10903 New Hampshire Avenue
Document Control Center - WO66-G609
Silver Spring, MD 20993-0002

January 22, 2016

Kaneka Corporation
% Mr. Christopher Sloan
Principal Consultant
Quintiles Consulting
1801 Rockville Pike, Suite 300
Rockville, Maryland 20852

Re: K152887

Trade/Device Name: Crosperio RX PTA Balloon Dilatation Catheter
Regulation Number: 21 CFR 870.1250
Regulation Name: Percutaneous Catheter
Regulatory Class: Class II
Product Code: LIT
Dated: December 18, 2015
Received: December 21, 2015

Dear Mr. Sloan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in

the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

<http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

Kenneth J. Cavanaugh -S

for

Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)

K152887

Device Name

Croserio RX PTA Balloon Dilatation Catheter

Indications for Use (Describe)

The Croserio RX PTA Balloon Dilatation Catheter is intended to dilate stenosis in the iliac, femoral, ilio-femoral, popliteal, infra-popliteal and renal arteries, and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. This device is also indicated for stent post-dilatation in the peripheral vasculature.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON A SEPARATE PAGE IF NEEDED.

FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.”

510(K) SUMMARY

Croserio RX PTA Balloon Dilatation Catheter

510(k) Submitter

Kaneka Corporation
Medical Device Division
1-12-32, Akasaka, Minato-ku
Tokyo, Japan
Contact Person: Toshihiko Motomine
Telephone: +81-3-5574-8023
Email: Toshihiko.Motomine@kaneka.co.jp

Official Correspondent

Christopher M. Sloan
Principal Consultant
Quintiles Consulting
1801 Rockville Pike, Suite 300
Rockville, MD 20852
Phone: (301) 272-3114
Facsimile: (301) 272-0004
Email: chris.sloan@quintiles.com

Date Prepared: September 10, 2015

Subject Device Name:

Trade Name	Crosperio RX PTA Balloon Dilatation Catheter
Common or usual name	Percutaneous (peripheral) transluminal angioplasty catheter
Classification name	Percutaneous catheter [21 CFR 870.1250; product code (LIT)]
Class	II
Classification Panel	Cardiovascular (74)

Predicate Devices:

- Metacross RX PTA Balloon Dilatation Catheter [K150865 (Kaneka Corporation)]
- Ultraverse[®] RX PTA Dilatation Catheter or “Ultraverse RX” [K131199 (Bard Peripheral Vascular Inc.)]

Device Description:

Crosperio RX PTA Balloon Dilatation Catheter (Crosperio RX) is a rapid exchange balloon dilation catheter, which consists of a distal tube, proximal tube, balloon, guidewire transition tube, radiopaque markers, hub, and strain relief. A balloon is attached to the distal end of the catheter and it can be inflated and deflated using the inflation device connected to the hub at the proximal end. Crosperio RX has a lumen (guidewire transition tube) at the distal end of the catheter through which a guidewire can be inserted, and also an opening along the balloon and distal tube to the guidewire port for the introduction of a guidewire.

The maximum compatible diameter of a guidewire used together with Crosperio RX in a PTA procedure is 0.014 inches; hence, sheath introducers with a minimum diameter of 4 Fr have been deemed to be compatible with Crosperio RX. The nominal inflated balloon diameters range from 1.5 mm to 4.0 mm with balloon working lengths of 20 mm to 200 mm. Two different catheter working lengths will be provided: 900 and 1500 mm.

The Crosperio RX is provided with the following accessory device:

- Flushing Needle: provided per one catheter device for the purpose of flushing and filling of the guidewire lumen with heparinized saline before use.

Indications for Use

The Crosperio RX is intended to dilate stenosis in the iliac, femoral, ilio-femoral, popliteal, infra-popliteal and renal arteries, and for the treatment of obstructive lesions of native or

synthetic arteriovenous dialysis fistulae. This device is also indicated for stent post-dilatation in the peripheral vasculature.

Comparison of Indications for Use to Predicate Devices

The indications for use of the Croserio RX is identical to that of the Metacross RX. The Croserio RX has the same intended use (percutaneous transluminal angioplasty) and similar indications for use as the Ultraverse RX. Therefore, the subject device, Croserio RX, may be considered substantially equivalent to predicate devices.

Comparison of Technological Characteristics to Predicate Devices

Technological Comparison to Predicate Devices

The Metacross RX has the following similarities to the predicate devices:

- Same intended use (same as Metacross RX and Ultraverse RX)
- Same indications for use (same as Metacross RX and similar to Ultraverse RX)
- Same target population (same as Metacross RX and Ultraverse RX)
- Same operating principle (same as Metacross RX and Ultraverse RX)
- Similar materials (similar to Metacross RX and Ultraverse RX)
- Same fundamental scientific technology (same as Metacross RX and Ultraverse RX)
- Same sterility assurance level and method of sterilization (same as Metacross RX and Ultraverse RX)

Performance Testing

To demonstrate substantial equivalence of Croserio RX to the predicate devices, the technological characteristics and performance criteria were evaluated using the bench testing recommendations outlined in the FDA Guidance Document “Class II Special Controls Guidance Document for Certain Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheters” dated September 8, 2010. The following *in vitro* tests were performed on the subject device:

Dimensional Verification, Balloon Preparation, Deployment and Retraction, Balloon Rated Burst Pressure, Balloon Fatigue (Repeat Balloon Inflations), Balloon Compliance, Balloon Inflation and Deflation Time, Catheter Bond Strength, Flexibility and Kink Test, Torque Strength, Radiopacity, Coating Integrity, Particulate Evaluation, Balloon Rated Burst Pressure (in Stent), and Balloon Fatigue (Repeat Balloon Inflations; in Stent), and Shelf Life Testing.

The results from these tests demonstrate that the technological characteristics and performance criteria of the Crosporio RX are adequate for the intended use of the device and that the device can perform in a manner equivalent to devices currently on the market with the same intended use.

Biocompatibility:

To demonstrate the biological safety of the body-contacting materials and substantial equivalence of the Crosporio RX to the predicate devices, the following biocompatibility testing was performed in accordance with ISO 10993-1:

Cytotoxicity, Sensitization, Intracutaneous reactivity (irritation), Systemic toxicity (acute), Pyrogenicity, Hemocompatibility (thrombogenicity, hemolysis, and immunology), and Genotoxicity (bacterial gene mutation assay, *in vitro* mammalian genotoxicity assay, and *in vivo* cytogenetics assay)

The results from these tests demonstrate that the Crosporio RX is biocompatible for its intended use similar to the predicate devices.

Conclusions:

The Crosporio RX met all the predetermined acceptance criteria of design verification and validation as specified by applicable standards, guidance, test protocols and/or customer inputs. The Crosporio RX PTA Balloon Dilatation Catheter is substantially equivalent to legally marketed predicate devices.